These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 28904004

  • 1. Jadomycins Inhibit Type II Topoisomerases and Promote DNA Damage and Apoptosis in Multidrug-Resistant Triple-Negative Breast Cancer Cells.
    Hall SR, Toulany J, Bennett LG, Martinez-Farina CF, Robertson AW, Jakeman DL, Goralski KB.
    J Pharmacol Exp Ther; 2017 Nov; 363(2):196-210. PubMed ID: 28904004
    [Abstract] [Full Text] [Related]

  • 2. Jadomycin breast cancer cytotoxicity is mediated by a copper-dependent, reactive oxygen species-inducing mechanism.
    Hall SR, Blundon HL, Ladda MA, Robertson AW, Martinez-Farina CF, Jakeman DL, Goralski KB.
    Pharmacol Res Perspect; 2015 Mar; 3(2):e00110. PubMed ID: 25729577
    [Abstract] [Full Text] [Related]

  • 3. [Stellera chamaejasme against multidrug resistance of triple-negative breast cancer MDA-MB-231 cell through Nrf2].
    Zeng R, Wang XX, Cui XH, Yang Q, Zhu XX, Wang YJ.
    Zhongguo Zhong Yao Za Zhi; 2024 Apr; 49(8):2222-2229. PubMed ID: 38812237
    [Abstract] [Full Text] [Related]

  • 4. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
    Issa ME, Hall SR, Dupuis SN, Graham CL, Jakeman DL, Goralski KB.
    Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527
    [Abstract] [Full Text] [Related]

  • 5. The selective effect of glycyrrhizin and glycyrrhetinic acid on topoisomerase IIα and apoptosis in combination with etoposide on triple negative breast cancer MDA-MB-231 cells.
    Cai Y, Zhao B, Liang Q, Zhang Y, Cai J, Li G.
    Eur J Pharmacol; 2017 Aug 15; 809():87-97. PubMed ID: 28506909
    [Abstract] [Full Text] [Related]

  • 6. Isolation of a jadomycin incorporating L-ornithine, analysis of antimicrobial activity and jadomycin reactive oxygen species (ROS) generation in MDA-MB-231 breast cancer cells.
    Forget SM, Robertson AW, Hall SR, MacLeod JM, Overy DP, Kerr RG, Goralski KB, Jakeman DL.
    J Antibiot (Tokyo); 2018 Aug 15; 71(8):722-730. PubMed ID: 29700425
    [Abstract] [Full Text] [Related]

  • 7. Jadomycins: A potential chemotherapy for multi-drug resistant metastatic breast cancer.
    Bonitto EP, McKeown BT, Goralski KB.
    Pharmacol Res Perspect; 2021 Dec 15; 9(6):e00886. PubMed ID: 34708587
    [Abstract] [Full Text] [Related]

  • 8. Deciphering the molecular mechanism underlying anticancer activity of coumestrol in triple-negative breast cancer cells.
    Zafar A, Singh S, Satija YK, Saluja D, Naseem I.
    Toxicol In Vitro; 2018 Feb 15; 46():19-28. PubMed ID: 28986287
    [Abstract] [Full Text] [Related]

  • 9. In vitro study on anti-proliferative and anti-cancer activity of picrosides in triple-negative breast cancer.
    Soni D, Wahi D, Verma S.
    Med Oncol; 2024 May 08; 41(6):143. PubMed ID: 38717628
    [Abstract] [Full Text] [Related]

  • 10. Transferrin Coated d-penicillamine-Au-Cu Nanocluster PLGA Nanocomposite Reverses Hypoxia-Induced EMT and MDR of Triple-Negative Breast Cancers.
    Shome R, Ghosh SS.
    ACS Appl Bio Mater; 2021 Jun 21; 4(6):5033-5048. PubMed ID: 35007052
    [Abstract] [Full Text] [Related]

  • 11. Dillenia suffruticosa dichloromethane root extract induced apoptosis towards MDA-MB-231 triple-negative breast cancer cells.
    Foo JB, Saiful Yazan L, Tor YS, Wibowo A, Ismail N, Armania N, Cheah YK, Abdullah R.
    J Ethnopharmacol; 2016 Jul 01; 187():195-204. PubMed ID: 27131434
    [Abstract] [Full Text] [Related]

  • 12. Induction of mitochondrial apoptotic pathway in triple negative breast carcinoma cells by methylglyoxal via generation of reactive oxygen species.
    Roy A, Ahir M, Bhattacharya S, Parida PK, Adhikary A, Jana K, Ray M.
    Mol Carcinog; 2017 Sep 01; 56(9):2086-2103. PubMed ID: 28418078
    [Abstract] [Full Text] [Related]

  • 13. A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer.
    Sambi M, Samuel V, Qorri B, Haq S, Burov SV, Markvicheva E, Harless W, Szewczuk MR.
    Drug Des Devel Ther; 2020 Sep 01; 14():1995-2019. PubMed ID: 32546966
    [Abstract] [Full Text] [Related]

  • 14. Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux.
    Vanhuyse M, Kluza J, Tardy C, Otero G, Cuevas C, Bailly C, Lansiaux A.
    Cancer Lett; 2005 Apr 28; 221(2):165-75. PubMed ID: 15808402
    [Abstract] [Full Text] [Related]

  • 15. Combination Organelle Mitochondrial Endoplasmic Reticulum Therapy (COMET) for Multidrug Resistant Breast Cancer.
    Milane LS, Dolare S, Ren G, Amiji M.
    J Control Release; 2023 Nov 28; 363():435-451. PubMed ID: 37717658
    [Abstract] [Full Text] [Related]

  • 16. The ascidian natural product eusynstyelamide B is a novel topoisomerase II poison that induces DNA damage and growth arrest in prostate and breast cancer cells.
    Liberio MS, Sadowski MC, Davis RA, Rockstroh A, Vasireddy R, Lehman ML, Nelson CC.
    Oncotarget; 2015 Dec 22; 6(41):43944-63. PubMed ID: 26733491
    [Abstract] [Full Text] [Related]

  • 17. Tackling the Cytotoxic Effect of a Marine Polycyclic Quinone-Type Metabolite: Halenaquinone Induces Molt 4 Cells Apoptosis via Oxidative Stress Combined with the Inhibition of HDAC and Topoisomerase Activities.
    Shih SP, Lee MG, El-Shazly M, Juan YS, Wen ZH, Du YC, Su JH, Sung PJ, Chen YC, Yang JC, Wu YC, Lu MC.
    Mar Drugs; 2015 May 20; 13(5):3132-53. PubMed ID: 26006712
    [Abstract] [Full Text] [Related]

  • 18. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L, Hansen HF, Wessel I, Nitiss JL, Schmidt G, Jensen PB, Sehested M, Jensen LH.
    Anticancer Drug Des; 2001 Dec 20; 16(6):305-15. PubMed ID: 12375883
    [Abstract] [Full Text] [Related]

  • 19. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, Menendez JA.
    Int J Oncol; 2008 Dec 20; 33(6):1165-76. PubMed ID: 19020749
    [Abstract] [Full Text] [Related]

  • 20. RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: necroptosis as a desperate programmed suicide pathway.
    Shahsavari Z, Karami-Tehrani F, Salami S, Ghasemzadeh M.
    Tumour Biol; 2016 Apr 20; 37(4):4479-91. PubMed ID: 26496737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.